Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP); Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 98 more

Conditions: Breast Cancer
Interventions: Axillary Reverse Mapping; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Rosacea
Interventions: PDI-320, PDI-320 Monad #1, PDI-320 Monad #2, Vehicle; Drug
Lead sponsor: PreCision Dermatology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: San Diego, California • Albuquerque, New Mexico

Conditions: Hidradenitis Suppurativa
Interventions: Ertapenem; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Increased Risk for Development of Breast Cancer
Interventions: bazedoxifene plus conjugated estrogens; Drug
Lead sponsor: Carol Fabian, MD; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Skin Diseases, Infectious
Interventions: PTK 0796, linezolid, moxifloxacin; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Fountain Valley, California • La Mesa, California • Oceanside, California + 4 more

Conditions: Undifferentiated Connective Tissue Disease
Interventions: Observation; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcers (DFU), Venous Stasis Ulcers (VSU)
Interventions: OASIS Wound Matrix; Device
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Fort Smith, Arkansas • St Louis, Missouri • St. George, Utah

Conditions: Arthritis, Rheumatoid
Interventions: SKI-O-703 capsule, Placebo capsule; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiomyopathy Due to Anthracyclines
Interventions: Allo-MSCs, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Stanford, California • Gainesville, Florida • Miami, Florida + 4 more

Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide; Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Cytology Specimen Collection Procedure, Diagnostic Laboratory Biomarker Analysis, Medical Chart Review; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Genital Herpes
Interventions: Famciclovir, Valacyclovir, Placebo matching famciclovir, Placebo matching valacyclovir; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 45 more

Conditions: Breast Cancer
Interventions: Core Exercise Promotion Program, Affect-based exercise prescription, Effort-based exercise prescription; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer, Osteoporosis
Interventions: calcium salts, cholecalciferol, zoledronic acid; Dietary Supplement · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 40 Years and older · Female only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 107
States / cities: Arroyo Grande, California • La Jolla, California • Mountain View, California + 80 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Epratuzumab; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 791 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 49
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Hemet, California + 44 more

Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Buffalo, New York

Conditions: Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions: Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II); Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Interventions: CUSA (Cavitronic Ultrasonic Surgical Aspirator); Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions: 2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap; Drug · Other
Lead sponsor: Cook County Health; Government
Eligibility: 16 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Nonhematological Malignancies, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastroesophageal Adenocarcinoma
Interventions: MLN8237 (Alisertib); Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Houston, Texas • Salt Lake City, Utah

Conditions: Marfan Syndrome
Interventions: Exercise Intervention Group, Control Group; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Axillary Reverse Mapping for Invasive Carcinoma of the Breast

ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers

An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Undifferentiated Connective Tissue Disease Registry

OASIS Wound Matrix (Oasis) Mechanism of Action

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

Stem Cell Injection in Cancer Survivors

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors

Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Marfan Syndrome Moderate Exercise Trial II